Detection of urological cancers by the signature of organic volatile compounds in urine, from dogs to electronic noses

• Published in: Current opinion in urology Vol. 33; no. 6; p. 437
• Main Authors: Gaye, Oumar, Fall, Cheikh Bintou, Jalloh, Mohamed, Faye, Babacar, Jobin, Marc, Cussenot, Olivier
• Format: Journal Article
• Language: English
• Published: United States 01.11.2023
• Subjects: Animals; Biomarkers; Dogs; Electronic Nose; Humans; Male; Urologic Neoplasms - diagnosis; Volatile Organic Compounds - urine
• ISSN: 1473-6586
• DOI: 10.1097/MOU.0000000000001128

Urine volatile organic compound (VOC) testing for early detection of urological cancers is a minimally invasive and promising method. The objective of this review was to present the results of recently published work on this subject. Organic volatile compounds are produced through oxidative stress and peroxidation of cell membranes, and they are eliminated through feces, urine, and sweat. Studies looking for VOCs in urine for the diagnosis of urological cancers have mostly focused on bladder and prostate cancers. However, the number of patients included in the studies was small. The electronic nose was the most widely used means of detecting VOCs in urine for the detection of urological cancers. MOS sensors and pattern recognition machine learning were more used for the composition of electronic noses. Early detection of urological cancers by detection of VOCs in urine is a method with encouraging results with sensitivities ranging from 27 to 100% and specificities ranging from 72 to 94%. The olfactory signature of urine from patients with urological cancers is a promising biomarker for the early diagnosis of urological cancers. The electronic nose with its ability to recognize complex odors is an excellent alterative to canine diagnosis and analytical techniques. Nevertheless, additional research improving the technology of Enoses and the methodology of the studies is necessary for its implementation in daily clinical practice.